Brain Stimulation for Depression in People Treated for Opioid Addiction
Tests magnetic brain stimulation against a sham version for depression in opioid use disorder.
Plain-language title generated from the registry record
Registry title: Helping Kentuckians Overcome Depression and Opioid Addiction With Brain Stimulation
Key facts
- Where
- Lexington, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07842601, who can take part
Where in United States
- University of KentuckyLexington, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Kentucky
- Trial code
- NCT07842601
- Record updated
- 25 September 2026
- Original description
This study will compare transcranial magnetic stimulation (TMS) with sham TMS in people with opioid use disorder who are taking buprenorphine and have major depressive disorder with ongoing depressive symptoms. The study will evaluate whether TMS improves depressive symptoms and reduces opioid craving. The study will also assess smoking behaviors, treatment acceptability, and any side effects related to TMS.Read full original descriptionShow less
Helping Kentuckians Overcome Depression and Opioid Addiction With Brain Stimulation
This study will compare transcranial magnetic stimulation (TMS) with sham TMS in people with opioid use disorder who are taking buprenorphine and have major depressive disorder with ongoing depressive symptoms. The study will evaluate whether TMS improves depressive symptoms and reduces opioid craving. The study will also assess smoking behaviors, treatment acceptability, and any side effects related to TMS.
Inclusion: 18-75 years of age; Willing and able to provide informed consent; Able to read and speak english; Opioid use disorder, in remission for at least a month; Diagnosis of major depressive disorder confirmed with the Mini-International Neuropsychiatric Interview (MINI, 7.02); Minimum score of 10 on the 17-item Hamilton Depression Rating Scale (HDRS-17); Opioid craving score of 5 or greater on a 0-10 scale; Stabilized on sublingual or depot buprenorphine for at least 8 weeks.
Exclusion: Magnetic resonance imaging (MRI) contraindications, including ferrous retainers, intracranial implants, or claustrophobia; Surgical procedure planned during the study period; Seizure disorder; any other acute medical or behavioral disorder that would preclude safe participation; Any other medical condition that could compromise participant well-being; Pregnant, nursing or planning to become pregnant during the study.